Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 7/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NRAS | P01111 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218696 | 0.81 | PDE7A (0.46) | PDE7ACHEK1PRKCZROCK1KCNH2 | |
| SCHEMBL2743890 | 0.79 | CHEK1 (0.46) | PDE7ACHEK1PRKCZROCK1ACVR1B | |
| SCHEMBL221586 | 0.74 | NMT1 (0.45) | PDE7ACHEK1PRKCZROCK1ACVR1B | |
| SCHEMBL5134246 | 0.73 | NMT1 (0.43) | CHEK1PRKCZROCK1ACVR1BTGFBR1 | |
| SCHEMBL6585068 | 0.73 | NOS1 (0.46) | — | |
| SCHEMBL7598921 | 0.72 | CYP1A1 (0.61) | — | |
| SCHEMBL27981561 | 0.71 | CHEK1 (0.44) | PDE7ACHEK1PRKCZROCK1ACVR1B | |
| SCHEMBL26889421 | 0.71 | CHEK1 (0.47) | PDE7ACHEK1PRKCZROCK1ACVR1B | |
| SCHEMBL19805885 | 0.71 | ROCK1 (0.54) | PDE7APRKCZROCK1KCNH2 | |
| SCHEMBL8572594 | 0.70 | PRKCZ (0.43) | PDE7ACHEK1PRKCZROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| WO-2018033639-A1 | LACTONE INTERMEDIATES OF NICOTINAMIDE RIBOSIDE AND NICOTINATE RIBOSIDE | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-02-22 | — | — | WO | disclosed |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| EP-3152220-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-12 | — | — | EP | disclosed |
| EP-3149016-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015186068-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015186114-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-10 | — | — | WO | disclosed |
| US-20150175645-A1 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | GLAXOSMITHKLINE LLC (US) | 2015-06-25 | — | — | US | disclosed |
| EP-2805719-A1 | Nicotinamide riboside and analogues thereof | Glaxosmithkline LLC (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-1910362-B9 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS INC (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007008548-A2 | METHODS AND RELATED COMPOSITIONS FOR TREATING OR PREVENTING OBESITY, INSULIN RESISTANCE DISORDERS, AND MITOCHONDRIAL-ASSOCIATED DISORDERS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20060276393-A1 | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060229265-A1 | Nicotinamide riboside and analogues thereof | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| WO-2006094246-A2 | N-ARYLMETHYL BENZAMIDE SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094237-A2 | ACRIDINE AND QUINOLINE DERVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094209-A2 | N-BENZIMIDAZOLYLALKYL-SUBSTITUTED AMIDE SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094235-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094248-A1 | ARYL-SUBSTITUTED CYCLIC SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006078941-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS OF USE THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | NNT, HADHB, NAMPT | PDE7A 561/4885CHEK1 4792/4885PRKCZ 553/4885 |
| US-20150175645-A1 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | SIRT1, NAMPT, SIRT2 | PDE7A 1862/4885CHEK1 2444/4885PRKCZ 3766/4885 |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | NNT, HADHB, NAMPT | PDE7A 561/4885CHEK1 4792/4885PRKCZ 553/4885 |
| US-20060276393-A1 | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders | SIRT2, SIRT1, SIRT3 | PDE7A 4462/4885CHEK1 2766/4885PRKCZ 4449/4885 |
| US-20060229265-A1 | Nicotinamide riboside and analogues thereof | SIRT1, NAMPT, SIRT2 | PDE7A 1862/4885CHEK1 2444/4885PRKCZ 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.